Geneoscopy, Inc., A Life Sciences Company Focused On The Development Of Diagnostic Tests For Gastrointestinal Health, Announced That It Submitted A Premarket Approval (Pma) Application To The Us Food And Drug Administration (Fda) For Its Noninvasive, Stool-Based, At-Home Screening Test To Detect Colorectal Cancer (Crc) And Advanced Adenomas (Aa) In Average-Risk Individuals. The Fda Designated The Test As A Breakthrough Device In January 2021.
